define investment

CEO of Portola Pharmaceuticals Inc (NASDAQ:PTLA) William Lis sold 269,299 shares of PTLA on 06/28/2017 at an average price of $55.43 a share. The total sale was $14.9 million.

Portola Pharmaceuticals Inc is a biopharmaceutical company. It develops & commercializes novel therapeutics in the areas of thrombosis, other hematologic disorders & inflammation for patients who currently have limited or no approved treatment options. Portola Pharmaceuticals Inc has a market cap of $3.22 billion; its shares were traded at around $56.42 with and P/S ratio of 98.64.

CEO Recent Trades:

CEO William Lis sold 269,299 shares of PTLA stock on 06/28/2017 at the average price of $55.43. The price of the stock has increased by 1.79% since.

CFO Recent Trades:

Executive VP and CFO Mardi Dier sold 93,392 shares of PTLA stock on 06/27/2017 at the average price of $55.46. The price of the stock has increased by 1.73% since.

Directors and Officers Recent Trades:

Director Jeffrey W Bird bought 119,442 shares of PTLA stock on 06/01/2017 at the average price of $31.85. The price of the stock has increased by 77.14% since.EVP, CBO Tao Fu sold 7,000 shares of PTLA stock on 06/26/2017 at the average price of $57.14. The price of the stock has decreased by 1.26% since.Executive Vice President John T Curnutte sold 60,000 shares of PTLA stock on 06/26/2017 at the average price of $57.88. The price of the stock has decreased by 2.52% since.Director Charles J Homcy sold 120,803 shares of PTLA stock on 06/23/2017 at the average price of $53.06. The price of the stock has increased by 6.33% since.10% Owner (mauritius) Pte Ltd Maxwell sold 1,700,000 shares of PTLA stock on 06/01/2017 at the average price of $34.4. The price of the stock has increased by 64.01% since.

For the complete insider trading history of PTLA, click here

define investment: The Hain Celestial Group, Inc.(HAIN)

Advisors’ Opinion:

  • [By Paul Ausick]

    The Hain Celestial Group Inc. (NASDAQ: HAIN) posted a new 52-week low of $31.70 on Thursday, down about 4.4% compared with Wednesday’s closing price of $33.16. The stock’s 52-week high is $56.99. Volume totaled more than 12.5 million shares, about 10 times the daily average of around 1.2 million. The organic food company said this morning that an accounting review has shown that the company does not need to change its accounting practices. Shares turned positive later in the day and are on track to close up about 1%.

  • [By Brian Stoffel]

    Shareholders of Hain Celestial (NASDAQ:HAIN) have endured a stomach-churning year. In August, the company announced that it would have to delay filing its quarterly report, saying: “The Company is currently evaluating whether the revenue associated with [Concessions that were granted to certain distributors]was accounted for in the correct period.”

  • [By Jason Hall]

    It’s been a very long time since Hain Celestial Group Inc. (NASDAQ:HAIN) reported its financial and operating results, having last reported on May 4, 2016. Since then, the company has delayed its filings multiple times because of accounting issues tied to the timing of revenue recognition.

  • [By Peter Graham]

    Mid cap natural and organic food stock Hain Celestial Group, Inc (NASDAQ: HAIN) reported Q4 and Fiscal Year 2017 earnings before the market opened Tuesdaywith Q4 results beating expectations and upbeat fiscal 2018 guidance. Q4 net sales fell 2% (or up 2% on a constant currency basis) to $725.1 million as net sales were impacted by $28.2 million from foreign exchange rate movements versus the prior year period:

  • [By Peter Graham]

    Mid cap natural and organic food stock Hain Celestial Group, Inc (NASDAQ: HAIN) reported long delayed earnings before the market opened this morning to avoid being delisted plusgave an update on an accounting probe. The last timethe Companyreported financial results was in May 2016. Then lastAugust, Hain Celestial Group delayed fiscal 2016 results, missed full-year guidance and announced potential accounting troubles stemming from revenue-recognition timing issues.

define investment: Sapiens International Corporation N.V.(SPNS)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than

define investment: PACCAR Inc.(PCAR)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Salesforce.com (CRM) , Paccar (PCAR) , Cummins (CMI) , ConocoPhillips (COP) , Adobe Systems (ADBE) , Annaly Capital (NLY) and Hewlett Packard Enterprise (HPE) .

  • [By JPMorgan]

    We are Neutral on PCAR as the company faces the risk of both lower volume and margin pressure from declining demand in its core NA HD truck business in 2016. However, we believe PCAR should command a premium valuation due to its track record of solid execution. In addition, PCAR pays out a normal and a special dividend which, in total, should equal ~50% of net income and currently offers a yield of 4.1% (JPMe total payout of ~$2.12/share) making it potentially attractive to income-oriented investors. 

  • [By Laurie Kulikowski]

    We rate PACCAR INC as a Buy with a ratings score of B-. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company’s strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, notable return on equity, attractive valuation levels and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. 

define investment: Legacy Reserves LP(LGCY)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Wednesday, the energy sector proved to be a source of strength for the market. Leading the sector was strength from Willbros Group Inc (NYSE: WG) and Legacy Reserves LP (NASDAQ: LGCY).

  • [By Lisa Levin]

    On Wednesday, the energy sector proved to be a source of strength for the market. Leading the sector was strength from Ocean Rig UDW Inc (NASDAQ: ORIG) and Legacy Reserves LP (NASDAQ: LGCY).

  • [By Lisa Levin]

    Energy shares surged around 1.85 percent in trading on Monday. Top gainers in the sector included Legacy Reserves LP (NASDAQ: LGCY), Whiting Petroleum Corp (NYSE: WLL), and Atwood Oceanics, Inc. (NYSE: ATW).

define investment: PNC Financial Services Group, Inc. (The)(PNC)

Advisors’ Opinion:

  • [By Teresa Rivas]

    PNC Financial Services (PNC) ended the week on a down note, despite better-than-expected first-quarter earnings.

    PNC said it earned $1.96 per share on revenue that climbed6% to $3.88 billion. Analysts were looking for earnings per share of $1.83 on $3.8 billion of revenue.

    A couple of analysts notes about the quarter are trickling in.

    Evercore ISI’s John Pancari reitearted an Outperform rating and $139 price target:

    We came away from 1Q17 results with greater confidence in our constructive view on the shares, particularly as balance sheet growth strengthens, NIM upside materializes, operative leverage improves, and credit remains contained.

    Raymond James’s Michael Rose reiterated a Market Perform rating on the stock:

    Excluding a positive valuation adjustment, recognition of deferred issuance costs related to the redemption of all REIT preferred securities on March 15, and fair value adjustments related to Visa Class B shares, operating EPS was also $1.96. Stronger than forecast revenue (both net interest income and fee revenue), a lower than forecast loan loss provision, and a lower than modeled tax rate more than offset higher noninterest expenses versus our model. Excluding losses on the sales of securities and the impact of mortgage servicing rights (MSR) hedging activity, we peg core EPS at $1.95.

    PNC closed down 0.2% to $115.80 on Thursday.

  • [By WWW.THESTREET.COM]

    Who is “the market” and how does it “want” to go down? Where’s the commandment that says stocks have to go lower? Who decides that today people who own stocks are by and large going to lose money? And why, of all things, does the market not want to go higher? Didn’t the CEO of the biggest bank, JPMorgan (JPM) , say things are great? Didn’t Wells Fargo (WFC) , after all of that scandal, still show some growth, a sign that it is putting the rough patch behind it? Didn’t Citigroup (C) have its best quarter in years? Wasn’t PNC Financial (PNC) even better, clear triumphs on every single line item? The word “perfect” comes to mind, as in Perfect National Corp. (Wells Fargo and Citigroup are part of TheStreet’s Action Alerts PLUS portfolio.)

  • [By Lisa Levin] Related WFC Why Bank ETFs Fell On Friday Despite Decent Earnings Phil's Stock World: Funtime Friday Earnings Season Starts Today Rising Book Values and Margins of Safety (GuruFocus)
    Related C Earnings Preview: Financial Giants BAC, GS, And MS Report Q2 Results This Week Why Bank ETFs Fell On Friday Despite Decent Earnings Palo Capital, Inc. Buys Citigroup Inc, Schlumberger, NetApp Inc, Sells Citrix Systems Inc, … (GuruFocus) Companies Reporting Before The Bell
    Wells Fargo & Co (NYSE: WFC) is estimated to report quarterly earnings at $1.02 per share on revenue of $22.51 billion.
    Citigroup Inc (NYSE: C) is projected to report quarterly earnings at $1.26 per share on revenue of $17.71 billion.
    JPMorgan Chase & Co. (NYSE: JPM) is expected to report quarterly earnings at $1.65 per share on revenue of $25.61 billion.
    PNC Financial Services Group Inc (NYSE: PNC) is projected to report quarterly earnings at $2.02 per share on revenue of $4.00 billion.
    First Republic Bank (NYSE: FRC) is estimated to report quarterly earnings at $1.1 per share on revenue of $675.70 million.
    First Horizon National Corp (NYSE: FHN) is projected to report quarterly earnings at $0.28 per share on revenue of $337.89 million.

     

define investment: Aurinia Pharmaceuticals Inc(AUPH)

Advisors’ Opinion:

  • [By Todd Campbell]

    After positive mid-stage trial data suggested earlier this year that it might be able to reshape the treatment of kidney failure in lupus patients, Aurinia Pharmaceuticals (NASDAQ:AUPH)has announced plans for a late-stage study that could eventually allow it to win regulatory OKs in the U.S., Europe, and Japan.

  • [By Lisa Levin] Related NVCN 18 Biggest Mid-Day Losers For Wednesday Legal Overhangs Keep Ladenburg Neutral On Neovasc Despite Positive Tiara Clinical Data Boston Scientific closes Neovasc transaction (Seeking Alpha)
    Related BSX Watch These 10 Huge Call Purchases In Monday Trade Wonderful Wearables Get Their Own ETF Boston Scientific closes Neovasc transaction (Seeking Alpha) Gainers
    Neovasc Inc (US) (NASDAQ: NVCN) rose 17.3 percent to $2.65 in pre-market trading after the company reported the close of its $75 million transaction with Boston Scientific Corporation (NYSE: BSX).
    aTyr Pharma Inc (NASDAQ: LIFE) shares rose 12.3 percent to $4.10 in pre-market trading after the company disclosed 'promising' signals in myopathies with Resolaris in exploratory trials.
    Globus Maritime Ltd (NASDAQ: GLBS) shares rose 10.1 percent to $6.90 in pre-market trading after climbing 5.03 percent on Monday.
    Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares rose 9.9 percent to $3.00 in pre-market trading. Aurinia Pharmaceuticals appointed Lorin Jeffry “Jeff” Randall to its board and Chairman of the Audit Committee.
    Ocean Rig UDW Inc. (NASDAQ: ORIG) shares rose 8.7 percent to $2.89 in pre-market trading after surging 19.82 percent on Monday.
    Full House Resorts, Inc. (NASDAQ: FLL) shares rose 5.1 percent to $2.08 in pre-market trading after declining 1.98 percent on Monday.
    Seadrill Ltd (NYSE: SDRL) rose 5.1 percent to $4.13 in pre-market trading after surging 3.15 percent on Monday.
    Noble Corporation (NYSE: NE) rose 5.1 percent to $7.60 in pre-market trading after declining 5.37 percent on Monday.
    Arbutus Biopharma Corp (NASDAQ: ABUS) rose 5.1 percent to $3.10 in pre-market trading. Arbutus issued additional data from its ARB-1467 Phase II
  • [By Lisa Levin]

    Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares shot up 24 percent to $4.60 after the company disclosed that Voclosporin met 48-week remission endpoints.

Leave a Reply

Your email address will not be published. Required fields are marked *